Research Paper Volume 12, Issue 18 pp 17902—17920

Figure 1. Overexpression of SBF2-AS1 correlates with clinicopathological features and poor prognosis in patients with NSCLC. (A) Volcano plot showing the upregulated and downregulated lncRNAs in the expression microarray (GSE19804 dataset). (B) Heatmap visualization of differentially expressed lncRNAs in normal vs lung cancer tissues (GSE19804 dataset). (C) Expression of SBF2-AS1 in normal and lung cancer tissues. Data represent log2 expression values. (D) Quantitative qRT-PCR analysis of SBF2-AS1 expression in 56 human NSCLC tissues and the paired non-cancerous tissues. ^**P<0.01 compared with non-cancerous group. (E) The expressions of SBF2-AS1 in NSCLC tissues and non-cancerous tissues were detected using northern blotting assay. (F) The expression levels of SBF2-AS1 in patients with different stage. ^**P<0.01 compared with I-II stage. (G) The expression levels of SBF2-AS1 in patients with or without metastasis. ^**P<0.01 compared with no metastasis. (H) Kaplan-Meier survival analysis of overall survival rate between NSCLC patients with low or high SBF2-AS1 expression. High SBF2-AS1 was a predictor for poor overall survival of NSCLC patients as analyzed at Kaplan-Meier plotter website.